Study of Pembrolizumab and Radiotherapy in Liver Cancer

Summary

This is a phase 2 study whose purpose is to assess the efficacy of the combination of pembrolizumab and stereotactic body radiotherapy (SBRT) in patients with advanced hepatocellular carcinoma (HCC) who have experienced disease progression after treatment with sorafenib.

Timeline

Start

2018-02-15

Primary completion

2024-02-15

Completion

2024-02-15

Outcome

Outcome not reported

Stopped: “The study was stopped due to the shift in systemic treatment paradigm for HCC precluding further enrolment.”

Drugs

Indications